Δ9-tetrahydrocannabinol
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04883255 | May 2023 → Jun 2026 overdue | HIV infectious disease | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 0 | NCT03944954 | Jul 2017 → Dec 2023 | substance-related disorder | Michael J. Wesley, PhD | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04931095 | Feb 2022 → Aug 2025 | alcohol-related disorders | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03529448 | Aug 2023 → Nov 2025 | glioblastoma | Grupo Español de Investigación en Neurooncología | Completed | No outcome recorded |
| Phase 1/2 | NCT05184478 | May 2022 → Dec 2023 | Tourette syndrome | Murdoch Childrens Research Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-06-26 | Tilray | Results Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations tilray.com ↗ |
| 2018-08-01 | Tilray | Results Tilray® 2:100 Product Shows Promise in Canada’s First Pediatric Study of Mixed THC/CBD Medical Cannabis Oil for Children with Drug-Resistant Epilepsy tilray.com ↗
In the participants who reached the target treatment dose there was a statistically significant reduction in motor seizures, and an increase in seizure-free days compared to those who did not reach the target dose. |
All press releases naming this drug 4 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Δ9-tetrahydrocannabinol | “The proposed research project is novel, innovative, and rigorous. It will combine the acute administration of Δ9-tetrahydrocannabinol (THC), the main psychoactive ingredient in...” NCT03944954 ↗4“Brownies containing 0 mg, 10 mg, or 25 mg Δ9-tetrahydrocannabinol (THC) combined with placebo drinks or alcohol-containing drinks, calculated to achieve breath alcohol...” PMID 42065887 ↗ May 2026 “Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have shown a clear synergistic antitumour effect with temozolomide and radiotherapy in preclinical glioma models.” NCT03529448 ↗ “The active medication was Δ9-tetrahydrocannabinol (THC) 10 mg/mL and CBD 15 mg/mL in peppermint-flavored medium-chain triglyceride oil.” PMID 40082070 ↗ Mar 2025 |
| Known as | dronabinol | “5-day course of orally-administered THC (dronabinol), 10 mg” NCT04883255 ↗ |
| Known as | tetrahydrocannabinol | “Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.” NCT05184478 ↗ |
| Known as | THC | “The proposed research project is novel, innovative, and rigorous. It will combine the acute administration of Δ9-tetrahydrocannabinol (THC), the main psychoactive ingredient in...” NCT03944954 ↗4“Brownies containing 0 mg, 10 mg, or 25 mg Δ9-tetrahydrocannabinol (THC) combined with placebo drinks or alcohol-containing drinks, calculated to achieve breath alcohol...” PMID 42065887 ↗ May 2026 “Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have shown a clear synergistic antitumour effect with temozolomide and radiotherapy in preclinical glioma models.” NCT03529448 ↗ “Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.” NCT05184478 ↗ “10 mg Δ9-tetrahydrocannabinol (THC)” NCT04883255 ↗ |
| Route | Oral | “5-day course of orally-administered THC (dronabinol), 10 mg” NCT04883255 ↗ |